

20 March 2020

As news continues to emerge regarding COVID-19, we thought it timely to provide an update to you.

For us at ANSTO, sustainable operations and the reliable supply of nuclear medicine to Australia is always a priority. Please find below an update on our contingencies in order to best manage the risks and impact of COVID-19.

We will continue to monitor the situation closely.

ANSTO staff are adopting the appropriate changes to minimise the risks of infection to our health products team.

We are working closely with all stakeholders to monitor our logistics and supply chain to ensure the priority remains on supply of essential nuclear medicine.

Tc-99m supply

To proactively avoid cross contamination within teams, we will be operating at a reduced capacity. This will impact our production of Tc-99m. However, we are developing a contingency plan with the nuclear medicine working group to ensure patient demand is met.

Our customer service team will be in contact with customers to discuss suitable options to minimise any patient impact.

Change to order cut off times for I-131 capsules and solutions

Commencing from Monday 30 March the order cut for I-131 capsules and solutions will be brought forward from 1.00pm the day of dispatch to 4.00pm the day before dispatch.

Please call the customer service team should you require further clarification regarding these cut off times.

Changes to our maintenance schedule

We will postpone the scheduled preventative maintenance shutdown of our nuclear medicine processing and distribution facility, also known as building 23 in order to ensure nuclear medicine is available to Australia. We are also reassessing the planned shutdown of OPAL for June. A decision will be made soon.

Keeping you informed

ANSTO will continue to provide regular updates to customers directly on our website. If you have any further questions please contact the customer service team on: 1800 251 572 or + 61 2 9717 9992